<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03768349</url>
  </required_header>
  <id_info>
    <org_study_id>18-006159</org_study_id>
    <nct_id>NCT03768349</nct_id>
    <nct_alias>NCT04144010</nct_alias>
  </id_info>
  <brief_title>PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer</brief_title>
  <official_title>PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imaging and staging of prostate cancer is critical for surgical and treatment planning. In
      this protocol we will image patients with suspected metastatic prostate cancer using
      11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) or
      F-18 labeled PSMA 1007 in order to demonstrate their utility in detecting prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Detection on PET/CT</measure>
    <time_frame>12 Months post PET/CT</time_frame>
    <description>Positive predictive value on a per-patient and per-region-basis of PSMA and C-11 choline PET/CT for detection of tumor location confirmed by histopathology/biopsy or conventional imaging follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of PSMA and C-11 choline PET on clinical management</measure>
    <time_frame>12 Months</time_frame>
    <description>Descriptive statistics will be used to evaluate the impact of PSMA and C-11 choline PET on clinical management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events attributable to PSMA</measure>
    <time_frame>12 Months</time_frame>
    <description>Adverse events will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PET/CT Ga-68 PSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ga-68 labeled PSMA-11 (or PSMA-HBED-CC) PET/CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PET/CT F-18 Labeled PSMA 1007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F-18 Labeled PSMA 1007 PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-68 PSMA11</intervention_name>
    <description>Ga-68 PSMA11 PET/CT for detection of tumor location</description>
    <arm_group_label>PET/CT Ga-68 PSMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 PSMA 1007</intervention_name>
    <description>F-18 PSMA 1007 PET/CT for detection of tumor location</description>
    <arm_group_label>PET/CT F-18 Labeled PSMA 1007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathological proven prostate adenocarcinoma.

          2. Rising PSA after definitive therapy with prostatectomy or radiation therapy (external
             beam or brachytherapy).

             a. Post radical prostatectomy (RP) - with or without radiation. i. PSA greater than or
             equal to 0.2 ng/mL measured more than 12 weeks after RP. ii. &gt; 3 months post-surgery
             b. Post-radiation therapy ASTRO-Phoenix consensus definition c. May or may not be
             castrate resistant (list prior therapies)

          3. Karnofsky performance status of 50 (or ECOG/WHO equivalent).

          4. CT or as part of the PET study or performed within one month of PSMA PET.

          5. Age &gt; 18.

          6. Ability to understand a written informed consent document, and the willingness to sign
             it.

        Exclusion Criteria:

          1. Undergoing investigational therapy for prostate cancer.

          2. Other ongoing treatments for prostate cancer including radiation therapy, chemotherapy
             or androgen deprivation. Androgen deprivation within the last 4 months excluding
             finasteride, dutasteride or other 5 alpha reductase inhibitors (excluding castrate
             resistant subjects).

          3. Unable to lie flat, still or tolerate a PET scan.

          4. Prior history of any other malignancy within the last 2 years, other than skin basal
             cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
             superficial bladder cancer.

          5. Contraindication to furosemide administration including prior allergy or adverse
             reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed
             if Furosemide is omitted as part of the PET imaging protocol if a second-generation
             scatter correction is available for the used PET device).

          6. Absence of PSA and total testosterone tests within 4 weeks.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Val Lowe, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Val Lowe</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>PET/CT</keyword>
  <keyword>PSMA</keyword>
  <keyword>C-11 Choline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The IPD data from this trial will be available to other researchers that will collate similar data from multiple sites to provide data to the FDA.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After completion of the trial and IPD will be available for 2 years.</ipd_time_frame>
    <ipd_access_criteria>Researchers collating data from multiple sites for submission to the FDA will be provided access to the IPD.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

